Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The price of Bristol-Myers Squibb Co (NYSE: BMY) closed at $42.6 in the last session, down -0.51% from day before closing price of $42.82. In other words, the price has decreased by -$0.51 from its previous closing price. On the day, 16.04 million shares were traded. BMY stock price reached its highest trading level at $43.15 during the session, while it also had its lowest trading level at $42.52.
Ratios:
We take a closer look at BMY’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.37 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 5.95. For the most recent quarter (mrq), Quick Ratio is recorded 1.11 and its Current Ratio is at 1.21. In the meantime, Its Debt-to-Equity ratio is 2.92 whereas as Long-Term Debt/Eq ratio is at 2.64.
On April 22, 2025, Cantor Fitzgerald started tracking the stock assigning a Neutral rating and target price of $55.Cantor Fitzgerald initiated its Neutral rating on April 22, 2025, with a $55 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 02 ’25 when Elkins David V sold 56,000 shares for $47.33 per share. The transaction valued at 2,650,480 led to the insider holds 167,379 shares of the business.
Elkins David V bought 56,000 shares of BMY for $2,648,800 on Sep 02 ’25. On Aug 02 ’25, another insider, Short Bartie Wendy, who serves as the EVP, Corporate Affairs of the company, sold 378 shares for $44.23 each. As a result, the insider received 16,719 and left with 5,066 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BMY now has a Market Capitalization of 86709559296 and an Enterprise Value of 124149563392. As of this moment, Bristol-Myers’s Price-to-Earnings (P/E) ratio for their current fiscal year is 17.19, and their Forward P/E ratio for the next fiscal year is 7.05. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.24. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.82 while its Price-to-Book (P/B) ratio in mrq is 4.97. Its current Enterprise Value per Revenue stands at 2.602 whereas that against EBITDA is 6.495.
Stock Price History:
The Beta on a monthly basis for BMY is 0.33, which has changed by -0.23614848 over the last 52 weeks, in comparison to a change of 0.20772064 over the same period for the S&P500. Over the past 52 weeks, BMY has reached a high of $63.33, while it has fallen to a 52-week low of $42.75. The 50-Day Moving Average of the stock is -6.29%, while the 200-Day Moving Average is calculated to be -15.33%.
Shares Statistics:
According to the various share statistics, BMY traded on average about 14.34M shares per day over the past 3-months and 15014260 shares per day over the past 10 days. A total of 2.04B shares are outstanding, with a floating share count of 2.03B. Insiders hold about 0.06% of the company’s shares, while institutions hold 82.27% stake in the company. Shares short for BMY as of 1760486400 were 30358285 with a Short Ratio of 2.12, compared to 1757894400 on 29470983. Therefore, it implies a Short% of Shares Outstanding of 30358285 and a Short% of Float of 1.49.
Dividends & Splits
The forward annual dividend rate for BMY is 2.48, which was 2.46 in the trailing 12 months. Against a Trailing Annual Dividend Yield of 0.05744979. The stock’s 5-year Average Dividend Yield is 3.75.
Earnings Estimates
The stock of Bristol-Myers Squibb Co (BMY) is currently in the spotlight, with 21.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is $1.57, with high estimates of $1.73 and low estimates of $1.39.
Analysts are recommending an EPS of between $6.64 and $6.18 for the fiscal current year, implying an average EPS of $6.36. EPS for the following year is $6.04, with 24.0 analysts recommending between $6.97 and $4.95.
Revenue Estimates
According to 20 analysts,. The current quarter’s revenue is expected to be $11.8B. It ranges from a high estimate of $12.06B to a low estimate of $11.54B. As of. The current estimate, Bristol-Myers Squibb Co’s year-ago sales were $11.89BFor the next quarter, 20 analysts are estimating revenue of $12.03B. There is a high estimate of $12.33B for the next quarter, whereas the lowest estimate is $11.59B.
A total of 25 analysts have provided revenue estimates for BMY’s current fiscal year. The highest revenue estimate was $48.03B, while the lowest revenue estimate was $46.77B, resulting in an average revenue estimate of $47.34B. In the same quarter a year ago, actual revenue was $48.3BBased on 24 analysts’ estimates, the company’s revenue will be $43.51B in the next fiscal year. The high estimate is $45.56B and the low estimate is $41.43B.
